📰 Impacts Questionnaire News
Page 2 - Impacts Questionnaire News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Impacts Questionnaire. Real-time updates on events, politics, business and more.
June 6, 2022
Poster presentation of Wake Up America: The Night & Day Impact of Insomnia, the largest U.S. survey of people with trouble sleeping and doctors, to discover...
May 3, 2022
QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable...
May 3, 2022
QUVIVIQ? is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningComprehensive nighttime
March 10, 2022
Allschwil, Switzerland - March 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that new data for daridorexant in patients with insomnia disorder, including long-term safety and efficacy data, will
February 25, 2022
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for QUVIVIQ (daridorexant) for the treatment of adult patients
February 25, 2022
Idorsia Ltd (SIX: IDIA) today announced the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of QUVIVIQ™ (daridorexant) as the first dual orexin receptor antagonist in the European Union (EU) for the t...
February 7, 2022
Daridorexant (50 mg) improves both nighttime symptoms and daytime functioning in people with insomnia disorder.
February 4, 2022
FRIDAY, Feb. 4, 2022 (HealthDay News) -- Daridorexant (50 mg) improves both nighttime symptoms and daytime functioning in people with insomnia disorder, according to a study published in the Feb.
January 28, 2022
Daridorexant, a newly approved dual orexin receptor antagonist, improves sleep onset in adult patients, new phase 3 data suggest.
January 21, 2022
The Idorsia insomnia drug, scheduled for release later this year, offers some relief for the millions of Americans living with insomnia.